Special Issue

Novel and Personalized Treatment Concepts in Gynecologic Cancer

Message from the Guest Editors

The field of gynecologic oncology has evolved greatly within the last years. The introduction of molecular analysis has changed the way we classify endometrial and epithelial ovarian cancers. Moreover, surgical treatment concepts have developed due to the introduction of the sentinel lymph node technique, allowing us to spare patients from unnecessary morbidities. Finally, predictive biomarkers such as BRCA mutations, homologous recombination deficiency, and microsatellite instability have revolutionized the treatment of a variety of gynecologic malignancies. In the precision medicine era, the further understanding of cancer genomics and the identification of predictive biomarkers are essential to achieve better health outcomes for women with gynecologic cancer. In this Special Issue, we aim to cover highly innovative findings and concepts within the field of gynecologic oncology, ranging from diagnostics to therapeutic approaches, that could improve the way we diagnose, classify, and/or treat gynecologic malignancies. A special focus will be precision medicine using molecular approaches and targeted treatments including Immunotherapy.

Guest Editors

Dr. Stephan Polterauer

Division of General Gynaecology and Gynaecological Oncology, Medical University of Vienna–Vienna General Hospital, 1090 Vienna, Austria

Dr. Christoph Grimm

Division of General Gynaecology and Gynaecological Oncology, Vienna General Hospital, Medical University of Vienna, 1090 Vienna, Austria

Deadline for manuscript submissions

closed (30 April 2024)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/105521

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm







Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

